Igm Biosciences Inc is a biotechnology company focused on the development and commercialization of innovative monoclonal antibody products for the treatment of various diseases, particularly in the fields of oncology and immunology. The company's proprietary technology platform allows for the design of next-generation antibody therapeutics that aim to enhance patient outcomes by improving efficacy and safety profiles. By leveraging its expertise in antibody engineering, Igm Biosciences is committed to addressing significant unmet medical needs through advanced therapeutic solutions that can offer new hope to patients. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of IGM Biosciences, Inc. (NASDAQ: IGMS) to Concentra Biosciences, LLC is fair to IGM shareholders. Under the terms of the proposed transaction, IGM shareholders would receive $1.247 in cash per share, plus one non-tradeable contingent value right, representing the right to receive additional proceeds under certain circumstances and conditions.
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock (“Common Stock”), plus one non-tradeable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and (ii) 80% of any net proceeds received within one year following closing from any disposition of certain of IGM Biosciences’ product candidates and intellectual property that occurs within one year following closing, each pursuant to a contingent value rights agreement (the “CVR Agreement”).
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 –
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences:
IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb executive as CEO. The company aims to extend its cash runway into 2027.
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperforming their larger-cap counterparts. However, potential for gains may be hindered by sluggish earnings and uncertain economic outlook.
